Cutaneous melanoma: a review of multifactorial pathogenesis, immunohistochemistry, and emerging biomarkers for early detection and management

LM Gosman, DA Țăpoi, M Costache - International Journal of Molecular …, 2023 - mdpi.com
Cutaneous melanoma (CM) is an increasingly significant public health concern. Due to
alarming mortality rates and escalating incidence, it is crucial to understand its etiology and …

PRAME updated: Diagnostic, prognostic, and therapeutic role in skin cancer

F Cassalia, A Danese, I Tudurachi, S Federico… - International Journal of …, 2024 - mdpi.com
Preferentially Expressed Antigen in Melanoma (PRAME), a member of the cancer/testis
antigen family, is central to the field of skin cancer diagnostics and therapeutics. As a …

Preferentially expressed antigen in melanoma is a multifaceted cancer testis antigen with diverse roles as a biomarker and therapeutic target

M Bose - International Journal of Translational Medicine, 2023 - mdpi.com
Preferentially expressed antigen in melanoma (PRAME) is a cancer testis antigen (CTA) that
is selectively expressed in certain somatic tissues, predominantly in the testis, and is …

PRAME expression in fibrosarcomatous dermatofibrosarcoma protuberans

T Ichiki, T Ito, S Shiraishi, Y Nakashima, T Nakahara… - Scientific Reports, 2024 - nature.com
PRAME (PReferentially expressed Antigen in MElanoma) was first identified as a malignant
melanoma-specific antigen. Recently, a few cases of fibrosarcomatous dermatofibrosarcoma …

Expression of Preferentially Expressed Antigen in Melanoma, a Cancer/Testis Antigen, in Carcinoma In Situ of the Urinary Tract

S Fujii, M Ishida, K Komura, K Nishimura, T Tsujino… - Diagnostics, 2023 - mdpi.com
Carcinoma in situ (CIS) of the urinary tract comprises 1–3% of all urothelial malignancies
and is often a precursor to muscle-invasive urothelial carcinoma (UC). This study aimed to …

Evaluation of PRAME immunohistochemistry in cutaneous vascular neoplasms reveals frequent expression in primary and post‐irradiation cutaneous angiosarcomas

A Krajisnik, N Rezaee, ER Duncan… - Journal of …, 2024 - Wiley Online Library
Background Preferentially expressed antigen in melanoma (PRAME) has been extensively
studied in cutaneous melanocytic tumors and has proven valuable as a diagnostic adjunct in …

Immunohistochemical profiles of dermatofibroma and dermatofibrosarcoma protuberans: A scoping review

CSC Hardy, A Razavi, N Nunez, W Fitzmaurice, L Dave… - medRxiv, 2024 - medrxiv.org
This review summarizes the immunohistochemical profiles of dermatofibroma (DF) and
dermatofibrosarcoma protuberans (DFSP) as reported by primary literature in the past 10 …

Malignant Melanotic Nerve Sheath Tumor–A Pitfall in the Diagnosis of Schwannoma

ME Kallen, R Koka, PF Hausner… - … Journal of Surgical …, 2024 - journals.sagepub.com
A 38-year-old woman underwent resection of an 8 cm retroperitoneal mass at an outside
hospital, which was deemed to be a schwannoma per follow-up clinical note. Intra …

PRAME Is a Multifaceted Cancer Testis Antigen with Diverse Roles as a Biomarker and Therapeutic Target

M Bose - 2023 - preprints.org
Abstract Preferentially expressed Antigen in Melanoma (PRAME) is a cancer testis antigen
(CTA) that is selectively expressed in certain somatic tissues, predominantly in the testis and …

Novel Driver Genes and Mutations in Lung Pecoma: A Case Report

TS Gerashchenko, KS Davydova… - Current Respiratory …, 2024 - benthamdirect.com
Introduction Perivascular epithelioid cell tumors (PEComa) are rare mesenchymal
neoplasms characterized by perivascular epithelioid cells. Despite their common occurrence …